Loading stock…

MBME GROUP Private Joint Stock Company (MBME) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

MBME GROUP Private Joint Stock Company

MBMEMarket cap $8.07BPrice $2.7

Country🇦🇪United Arab Emirates

SectorFinancials

MBME builds digital health and insurance-tech platforms across the UAE and wider Gulf region, connecting insurers, hospitals, and patients on one system. It processes millions of claims yearly, quietly powering the region's healthcare payments infrastructure.

In Bastion Portfolios?

52W Return0%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)+75%10

Rev CAGR (3y)+54%10

Rev CAGR (5y)+38%10

Earnings Forecast

EPS Growth Y+1na–

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-658%1

Net Income Margin-21582%1

Free Cash Flow Margin-507%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-8%1

ROA-8%1

Earnings Stability88

GEAR+

Not enough data to calculate the GEAR+ rating.

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV4.44

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yieldna–

Dividend Yieldna–

Momentum

Short term

1 month return0%8

3 month return0%6

YTD return0%5

Mid term

Price vs 52wHighna–

1 year return0%5

Long term

3 year return-0%3

5 year return-4%3

Risk Shield

Price Risk

Betana–

Volatilityna–

Free Cash Flow

Free Cash Flow Margin-507%1

Free Cash Flow Yieldna–

Quality

ROCE-0%1

Earnings Stability88

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

MBMEMBME GROUP Private Joint Stock

Revenue FY25$0M

GROWTH RATING↗

——

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+75%10

Revenue, next 3Y, CAGR+54%10

Revenue, next 5Y, CAGR+38%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26Ena–

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 54%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 54%/yr from here.

The runway holds up: revenue is set to grow 38%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 100% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MBMEMBME GROUP Private Joint Stock

Total return Current−0.02%

Price return Current−0.02%

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return0%8

3-month return0%6

YTD return0%5

MID & LONG-TERM▾SCORE

% of 52-week highna–

1-year return0%5

3-year return-0%3

5-year return-4%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

It's up 0% over the past year, but 100% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (+0%) and so far this year (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+0% over three years and -3.6% over five), behind 70% of the market.

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on MBME GROUP Private Joint Stock Company. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MBMEMBME GROUP Private Joint Stock

Revenue FY25$0M

GROWTH RATING↗

——

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+75%10

Revenue, next 3Y, CAGR+54%10

Revenue, next 5Y, CAGR+38%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26Ena–

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 54%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 54%/yr from here.

The runway holds up: revenue is set to grow 38%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 100% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MBMEMBME GROUP Private Joint Stock

Total return Current−0.02%

Price return Current−0.02%

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return0%8

3-month return0%6

YTD return0%5

MID & LONG-TERM▾SCORE

% of 52-week highna–

1-year return0%5

3-year return-0%3

5-year return-4%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

It's up 0% over the past year, but 100% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (+0%) and so far this year (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+0% over three years and -3.6% over five), behind 70% of the market.

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on MBME GROUP Private Joint Stock Company. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community